Antibiotice (LTS:0DMW) Cyclically Adjusted Revenue per Share: lei0.19 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0DMW Antibiotice SA LTS:0DMW
79 GF Score
Price lei0.51
GF Value lei0.53
! 7 Warning Signs
View Full Analysis

What is Antibiotice Cyclically Adjusted Revenue per Share?

Antibiotice LTS:0DMW 79 Cyclically Adjusted Revenue per Share is lei0.19 as of Jun. 2026. GuruFocus rates LTS:0DMW with a GF Score™ of 79/100 and a GF Value™ of lei0.53. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Antibiotice's adjusted revenue per share for the three months ended in Jun. 2026 was lei0.243. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is lei0.19 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Antibiotice's average Cyclically Adjusted Revenue Growth Rate was 6.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Antibiotice was 8.60% per year. The lowest was 7.50% per year. And the median was 8.00% per year.

As of today (2026-08-26), Antibiotice's current stock price is lei0.5054. Antibiotice's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was lei0.19. Antibiotice's Cyclically Adjusted PS Ratio of today is 2.66.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Antibiotice was 4.73. The lowest was 0.81. And the median was 1.79.


Antibiotice  (LTS:0DMW) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Antibiotice's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.5054/0.19
=2.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Antibiotice was 4.73. The lowest was 0.81. And the median was 1.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Antibiotice Cyclically Adjusted Revenue per Share Related Terms


Antibiotice Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Antibiotice's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antibiotice Cyclically Adjusted Revenue per Share Chart

Antibiotice Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.55 0.24 0.14 0.16

Antibiotice Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.15 0.16 0.22 0.19

LTS:0DMW vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Antibiotice's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antibiotice Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Antibiotice's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Antibiotice's Cyclically Adjusted PS Ratio falls into.


LTS:0DMW
79GF Score
Antibiotice SA LTS:0DMW
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antibiotice Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Antibiotice's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.243/333.9520*333.9520
=0.243

Current CPI (Jun. 2026) = 333.9520.

Antibiotice Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.124 241.428 0.172
201612 0.157 241.432 0.217
201703 0.083 243.801 0.114
201706 0.137 244.955 0.187
201709 0.130 246.819 0.176
201712 0.153 246.524 0.207
201803 0.088 249.554 0.118
201806 0.147 251.989 0.195
201809 0.124 252.439 0.164
201812 0.184 251.233 0.245
201903 0.097 254.202 0.127
201906 0.160 256.143 0.209
201909 0.104 256.759 0.135
201912 0.219 256.974 0.285
202003 0.110 258.115 0.142
202006 0.108 257.797 0.140
202009 0.085 260.280 0.109
202012 0.204 260.474 0.262
202103 0.098 264.877 0.124
202106 0.142 271.696 0.175
202109 0.126 274.310 0.153
202112 0.179 278.802 0.214
202203 0.191 287.504 0.222
202206 0.179 296.311 0.202
202209 0.170 296.808 0.191
202212 0.180 296.797 0.203
202303 0.267 301.836 0.295
202306 0.204 305.109 0.223
202309 0.219 307.789 0.238
202312 0.205 306.746 0.223
202403 0.272 312.332 0.291
202406 0.250 314.175 0.266
202409 0.232 315.301 0.246
202412 0.252 315.605 0.267
202503 0.240 319.799 0.251
202506 0.257 322.561 0.266
202509 0.201 324.800 0.207
202512 0.264 324.054 0.272
202603 0.203 330.213 0.205
202606 0.243 333.952 0.243

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of lei0.19 mean?
Antibiotice (LTS:0DMW) has a Cyclically Adjusted Revenue per Share of lei0.19 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Antibiotice and its competitors.
Is Antibiotice's Cyclically Adjusted Revenue per Share too high?
Antibiotice's current Cyclically Adjusted Revenue per Share is lei0.19. Overall, Antibiotice has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Antibiotice's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Antibiotice's Cyclically Adjusted Revenue per Share of lei0.19 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Antibiotice and its competitors. Antibiotice's current Cyclically Adjusted Revenue per Share is lei0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antibiotice stock overvalued right now?
Antibiotice (LTS:0DMW) has a current Cyclically Adjusted Revenue per Share of lei0.19. The stock's GF Value™ is lei0.53, compared to a current price of lei0.51 — trading 4.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is lei0.19. Antibiotice's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Antibiotice (LTS:0DMW), the current Cyclically Adjusted Revenue per Share is lei0.19 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Antibiotice (LTS:0DMW) Overvalued in 2026?

Based on GuruFocus' analysis, Antibiotice stock appears to be undervalued. The current stock price of lei0.51 is trading 4.6% below its estimated GF Value™ of lei0.53.

Key valuation signals for LTS:0DMW:

  • Cyclically Adjusted Revenue per Share: lei0.19
  • GF Value™: lei0.53 vs. price of lei0.51 (4.6% below fair value)
  • GF Score™: 79/100 with 7 warning signs

No single metric tells the full story. See the LTS:0DMW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Antibiotice Business Description

Other Exchanges ATB:Romania
Address 1 Valea Lupului Street, Iasi, ROU, 707410
Antibiotice SA is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).
79GF Score

Get the complete analysis for LTS:0DMW

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei0.51
Price
lei0.53
GF Value